Medical imaging technology company Polarean Imaging plc (AIM: POLX) announced on Monday that it has expanded its commercial agreement with Ascend Imaging LLC, extending coverage of its Xenon MRI platform from four to 19 US states.

Under the enhanced terms, Ascend Imaging will continue to serve as a non-exclusive, independent manufacturer's representative, supporting sales promotion, customer engagement and deal execution. The partnership aims to accelerate Polarean's commercial momentum across key US regions.

Ascend Imaging, which specialises in radiology and radiation oncology solutions incorporating advanced imaging and AI technologies, brings extensive healthcare relationships that align with Polarean's expansion strategy in functional lung imaging.

Polarean, a leader in hyperpolarisation science, develops and commercialises non-invasive MRI technologies for visualising lung function. Its FDA-approved hyperpolarised Xenon contrast agent, XENOVIEW, enables advanced respiratory imaging for adults and children aged six and older, addressing the needs of over 500 million people globally affected by chronic respiratory disease.